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Abstract
Background: Remodeling of the extracellular matrix is one of the most striking features observed
in the uterus during the estrous cycle and after hormone replacement. Versican (VER) is a
hyaluronan-binding proteoglycan that undergoes RNA alternative splicing, generating four distinct
isoforms. This study analyzed the synthesis and distribution of VER in mouse uterine tissues during
the estrous cycle, in ovariectomized (OVX) animals and after 17beta-estradiol (E2) and
medroxyprogesterone (MPA) treatments, either alone or in combination.
Methods: Uteri from mice in all phases of the estrous cycle, and animals subjected to ovariectomy
and hormone replacement were collected for immunoperoxidase staining for versican, as well as
PCR and quantitative Real Time PCR.
Results: In diestrus and proestrus, VER was exclusively expressed in the endometrial stroma. In
estrus and metaestrus, VER was present in both endometrial stroma and myometrium. In OVX
mice, VER immunoreaction was abolished in all uterine tissues. VER expression was restored by
E2, MPA and E2+MPA treatments. Real Time PCR analysis showed that VER expression increases
considerably in the MPA-treated group. Analysis of mRNA identified isoforms V0, V1 and V3 in the
mouse uterus.
Conclusion: These results show that the expression of versican in uterine tissues is modulated by
ovarian steroid hormones, in a tissue-specific manner. VER is induced in the myometrium
exclusively by E2, whereas MPA induces VER deposition only in the endometrial stroma.
Background
The estrous cycle is orchestrated by ovarian sex hormones
[1]. In the mature mouse, estrogen (E2) produced during
estrus stimulates epithelial cell proliferation and synthesis
of progesterone receptors (PR). On the other hand, pro-
gesterone (P4) inhibits epithelial proliferation while stim-
ulating the multiplication of stromal cells that
characterizes the beginning of decidualization [2,3]. The
combined action of E2 and P4 prepares uterine tissues for
blastocyst implantation.
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Estrogen receptors (ERα and ERβ) and progesterone
receptors (PRA, PRB and PRC) are transcription factors
that regulate gene expression by direct binding to DNA
regulatory sequences and by specific interactions with co-
activators and/or co-repressor proteins [4,5]. In response
to the normal changes in the levels of E2 and P4, the
endometrium and myometrium undergo extensive cellu-
lar and extracellular modification [6].
The ECM is a complex structure of macromolecules capa-
ble of self-assembly and is composed predominantly of
collagens, non-collagenous multiadhesive glycoproteins,
elastin, hyaluronan and proteoglycans [7]. The endome-
trial ECM plays important roles in endometrial deciduali-
zation, embryo implantation, trophoblast cell invasion
and the maintenance of gestation [8-10]. Previous reports
have documented the remodeling of collagen [11-14], as
well as glycosaminoglycans and proteoglycans in the
mouse uterus during early pregnancy [15,16]. Salgado et
al. [17] have shown the differential distribution of four
members of the small leucine-rich proteoglycan (SLRP)
family in mouse endometrium and myometrium during
the estrous cycle, suggesting that their expression in the
uterine ECM is modulated by ovarian hormones. San
Martin et al. [18] also detected hyaluronan (HA) and ver-
sican (VER) in endometrial stroma during the peri-
implantation period, when angiogenesis, cell migration,
trophoblast invasion and cell proliferation occur. After
implantation, HA disappeared from the decidual region
immediately surrounding the implantation chamber,
whereas VER accumulated in the same region, suggesting
this proteoglycan plays a role in proliferation and differ-
entiation of endometrial fibroblasts into decidual cells,
and may influence trophoblast invasion.
VER is a large chondroitin sulfate proteoglycan that
belongs to the family of hyaluronan-binding proteogly-
cans termed hyalectins, and is found in many soft tissues.
The middle region of the core protein is encoded by two
large exons that specify the chondroitin sulfate attach-
ment regions [19,20]. RNA splicing occurs in the two GAG
attachment domains, encoded by exons 7 (αGAG) and 8
(βGAG), giving rise to four distinct isoforms termed V0,
V1, V2 and V3. V0 possesses both exons 7 and 8, V1 only
exon 8, V2 only exon 7 and V3 possesses neither [21]. The
interaction between VER and hyaluronan (HA) is medi-
ated by the N-terminal G1 globular domain, while the car-
boxy-terminal globular domain (G3) consists of a C-type
lectin adjacent to two epidermal growth factor domains
and a complement regulatory region. VER interacts with
other ECM molecules, such as tenascin-R, collagen I,
fibronectin and the elastic fiber-associated proteins fibril-
lin-1 and fibulin-2 [22]. Fibrillin-1 is present in the
endometrial stroma in estrus and diestrus [23]. In addi-
tion, VER binds to chemokines and cell surface receptors
including  β1-integrin, CD44, epidermal growth factor
receptor and selectins [24]. These interactions facilitate
essential biological processes, including cell migration
[20].
The expression of different VER isoforms influences the
formation of the extracellular matrix network and might
modulate cell-matrix and cell-cell interactions [19]. More-
over, RNA splicing patterns suggest distinct functions for
different domains of the protein. V0/V1 isoforms show
similar properties with respect to cell anti-adhesion, pro-
liferation and growth, and resistance to apoptosis. V2 is
known to inhibit cell growth and proliferation, and to be
expressed only in the nervous system, as the major iso-
form in adult brain [25]. The truncated isoform V3, some-
times called "versicant", is thought to possess pro-
adhesive properties, due to the lack of the highly nega-
tively charged chondroitin sulfate side chains [26].
Previous reports describe changes in the distribution of
HA and VER in human and murine cervix during late preg-
nancy and parturition [27,28]. In the female rodent repro-
ductive system, VER distribution and the expression of its
isoforms were shown for the first time by Russel et al. [29]
in the mouse ovary. However, little is known about VER
expression and function in the non-pregnant uterus. The
major objectives of the present study were (i) to analyze
whether E2 and P4 modulate the expression and distribu-
tion of VER in the uterine tissues of mice and (ii) to char-
acterize VER isoforms in the mouse uterus.
Methods
Tissue collection
Forty two Swiss female mice, aged 3–5 months, were used.
Animals were housed in a 12-h light: 12-h dark, tempera-
ture-controlled (22°C) environment, with free access to
food and water. The stages of the estrous cycle were deter-
mined by vaginal smears. Animals in proestrus, estrus,
metaestrus and diestrus, and ovariectomized animals sub-
mitted or not to hormone replacement were anesthetized
with an intraperitoneal injection of tribromoethanol
(Avertin®) (Aldrich Chemical Company, Inc., Milwaukee,
Wisconsin, USA; 0,025 mL/g body weight). The uteri were
subsequently removed, cut with razor blades and immedi-
ately immersed in a fixative solution or in RNAlater solu-
tion and stored at -20°C. National guidelines for
laboratory animal care were followed, and all experiments
were approved by the Institute of Biomedical Sciences
Animal Ethics Committee (authorization number, 144/
2002).
Ovariectomy and hormone replacement
The general protocol adopted here was adapted from
Domino and Hurd [30]. Three different doses for 17β-
estradiol (E2; 1, 10 and 100 μg) and medroxyprogester-Reproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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one acetate (MPA; 0.25, 0.5 and 1 mg) were tested. Vagi-
nal smear features and uterine morphology were used to
establish the most appropriate protocol.
1. Tissue collection twenty days after ovariectomy.
2. Pre-treatment with daily priming doses of E2 (Sigma-
Aldrich, St. Louis, Missouri, USA) (10 μg/animal), diluted
in mineral oil (Schering-Plough), for three days, followed
by a two-day rest and daily injections of E2 (10 μg/ani-
mal) during four consecutive days.
3. Pre-treatment with daily priming doses of E2, followed
by a resting period and daily injections of MPA (500 μg/
animal) (Pharmacia & Upjohn), diluted in distilled water,
during four consecutive days.
4. Same pre-treatment and resting period as the previous
groups, followed by daily injections of both E2 and MPA
during four consecutive days.
5. Control group received injections of vehicle alone
(mineral oil) for three days, followed by a two-day rest
and daily oil injections during four consecutive days.
All injections were sub-cutaneous in a 100 μl volume.
Twenty four hours after the last injection, the mice were
anesthetized and the uteri were collected as described
above.
Light microscopy processing
Samples were fixed at 4°C for 3 h in Methacarn (absolute
methanol, chloroform and glacial acetic acid; 6:3:1),
rinsed with absolute ethanol, and embedded in Paraplast
(Oxford, St. Louis, Missouri, USA) at 60°C. Samples were
cut into 5 μm sections, adhered to glass slides using 0.1%
poly-L-lysine (Sigma, St. Louis, Missouri, USA) and then
dried at 37°C.
Immunohistochemistry
Immunohistochemistry was performed according to a
previously established protocol [17]. Briefly, sections
were deparaffinized, hydrated and treated with 3% (v/v)
H2O2 in PBS (30 min) to block endogenous peroxidase
activity. They were subsequently incubated with chon-
droitinase ABC from proteus vulgaris (Seikagaku, Tokyo,
Japan), diluted in 20 mM Tris-HCl buffer pH 6.0 (1 h at
37°C), prior to incubation with primary antibody. Non-
specific staining was blocked by incubating the sections (1
h) with normal goat serum, diluted 1:1 (v/v) in PBS –
10% BSA (w/v) (room temperature). Rabbit anti-VER pol-
yclonal antibody (Chemicon International, Temecula,
CA, USA) recognizing isoforms V0 and V1 was diluted
1:500 in PBS – 0.3% (v/v) Tween 20 and incubated over-
night (4°C). The sections were then incubated with
biotin-conjugated secondary anti-rabbit IgG (1:2000)
(Rockland, Gilbertsville, Pennsylvania, USA), diluted in
PBS (v/v) (1 h at room temperature) and with streptavi-
din-peroxidase ABC complex (Vector Labs, Burlingame,
California, USA) (1 h at room temperature), according to
the manufacturer's instructions. Peroxidase was visualized
using 0.03% (w/v) 3,3'-diaminobenzidine in PBS with
0.03% (v/v) H2O2. The sections were counterstained with
Mayer's haematoxylin. Negative controls included replac-
ing the primary antibodies with the respective non-
immune serum at similar concentrations or omitting the
primary antibody step from the protocol.
A Nikon Eclipse E600 microscope was used for examining
sections. Images were captured using a digital camera
(Cool SNAP-Procf color; Roper Scientific, Trenton, New
Jersey, USA) and Image Pro Plus software (Media Cyber-
netics, Silver Spring, Maryland, USA).
mRNA extraction and semi-quantitative real-time PCR
For the molecular biology experiments, the phases of
estrus – highest estrogen levels – and diestrus – highest
progesterone levels – were chosen to represent the estrous
cycle.
Uteri samples (n = 5) were immersed in RNAlater solution
and stored at -20°C. Upon use, they were crushed in a
steel mortar and pestle set (Fisher Scientific International,
Inc, Hampton, New Hampshire, USA) precooled in dry
ice. The crushed samples were transferred to sterile micro-
fuge tubes and total RNA was extracted using Trizol rea-
gent (Invitrogen, Calbard, California, USA) following the
manufacturer's instructions. Reverse transcription was
performed with AffinityScript QPCR cDNA Synthesis kit
(Stratagene, Cedar Creek, TX, USA) and 1 μg of total RNA.
The cDNA samples were used to determine which VER
isoforms were expressed in the mouse uterus by PCR
amplification using the Platinum Taq DNA Polymerase
kit (Invitrogen) and specific primers [29]. GAPDH was
used as internal control and Universal Mouse Reference
RNA (Stratagene) was used as positive control in the PCR
amplification experiments. The relative expression of VER
mRNA was determined as described previously [31]. The
relative levels of mRNA of the tested gene were estimated
in duplicate samples by fluorescence quantified with the
ABI Prism 7500 sequence detector (Applied Biosystems).
Reactions were performed in a total volume of 25 μl con-
taining 10 ng of cDNA and 450 nM primers in a reaction
buffer containing SYBR Green PCR master mix (Strata-
gene). All Ct values were normalized using GAPDH and
the results were expressed as fold-induction relative to the
expression of the control, the calibrator sample, arbitrarily
set to 1. Primer sequences are given in Table 1.Reproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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Statistical analysis
The unpaired t test was used to determine significant dif-
ferences between groups and was performed using Prism
3.0 (GraphPad Software, San Diego, California, USA).
Multiple comparisons were performed by ANOVA fol-
lowed by the Student-Newman-Keuls test.
Results
Two morphologically distinct compartments can be iden-
tified in the endometrial stroma, herein denoted as super-
ficial and deep, as described previously [17].
Immunolocalization of versican
In proestrus (Figure 1A and 1E) and diestrus (Figure 1D
and 1H), the immunoreaction for VER was observed as a
dense network in the endometrial stroma, but was absent
in the myometrium. In both groups, especially diestrus,
staining was stronger in the superficial stroma with only
traces at the interface between the deep stroma and the
myometrium.
In estrus (Figure 1B and 1F) and metaestrus (Figure 1C
and 1G), the immunoreaction was present in both super-
ficial and deep stroma, as well as in the internal layer of
the myometrium. The reaction seemed to be weaker in
metaestrus.
In the E2-treated group, strong immunoreaction was
present in the whole endometrial stroma, except in areas
of edema. The reaction was observed as a network in the
intercellular spaces. Staining was also observed at the
interface between the deep stroma and the myometrium,
as well as in the myometrial internal layer (Figure 2A and
2G).
In the MPA-treated group, VER was seen exclusively in the
superficial stroma as a dense network in the extracellular
spaces, as well as in the cytoplasm of endometrial fibrob-
lasts (Figure 2B and 2H).
In the E2+MPA-treated group, VER was present as a net-
work of thin filaments in the ECM in the whole endome-
trial stroma, except at the interface between the deep
stroma and the myometrium of the antimesometrial
region. The immunoreaction was present in both layers of
the myometrium (Figure 2C and 2I).
In ovariectomized (ovx) animals (Figure 2D), VER immu-
noreactivity was absent from uterine tissues. In the oil-
control group (Figure 2E and 2J), immunoreaction was
present in a narrow area of the superficial stroma, mainly
in the antimesometrial region.
Relative expression of versican mRNA
VER mRNA was estimated by real time PCR of uterine
cDNA obtained during the estrous cycle or after ovariec-
tomy or hormone replacement (n = 5). Figure 3A shows
that the relative expression of VER was ~3 fold higher in
estrus than in diestrus (p < 0.05). After ovariectomy, VER
mRNA was increased in the MPA-treated group (~2 fold;
p < 0.001). The treatment with E2 or E2+MPA did not sig-
nificantly alter VER mRNA, if compared to estrus. How-
ever, oil injections significantly decreased VER mRNA
expression when compared to Ovx and E2 (Figure 3B).
Expression of versican isoforms
mRNA analysis (Figure 4A–C) showed that V0, V1 and V3
are all expressed in the uterus. V2 was not detected in the
estrous cycle or following hormone treatment. In general,
Table 1: Mouse oligonucleotide primers (5'→3')
Gene Forward (F) and Reverse (R) primers Amp. size Genbank #
*GAPDH F:848TCTGAGGGCCCACTGAAG865;
R:1047AGGGTTTCTTACTCCTTGGAGG1068
221 bp NM_001001303
*Versican F:9532TCCTGATTGGCATTAGTGAAG 9552;
R:9672CTGGTCTCCGCTGTATCC 9689
158 bp NM_001081249
V0 F:3759TTCACAGAACGCCACCCTTGAGTCC3783;
R:4363CTAGCTTCTGCAGCTTCCGGGTCC 4386
628 bp NM_28599
V1 F:1031GCAGCTTGGAGAAATGGCTTTGACC1055;
R:4363CTAGCTTCTGCAGCTTCCGGGTCC 4386
443 bp NM_28599
V2 F:3856TCCTGGAGAATCTGTAACACAGCACCC3882;
R:9364CTCGGTAGGATAACAGGTGCCTCCG9388
307 bp NM_28599
V3 F:1024ACTTCAGGCAGCTTGGAGAAATGGC1048;
R:9410ACTGGTCTCCGCTGTATCCAGGTGC9434
302 bp NM_28599
V0, V1, V2 and V3 are alternative splicing variants of the versican gene. *primers used for real-time PCR analysis.Reproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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Immunoperoxidase for versican Figure 1
Immunoperoxidase for versican. (A) proestrus and (D) diestrus: the immunoreaction is seen as a dense network in the 
endometrial stroma, but absent in the myometrium. In both groups, the immunolabeling is stronger in the superficial stroma 
(SS) and only traces are observed in the interface between deep stroma (DS) and myometrium (M); (B) estrus and (C) metaes-
trous: the immunoreaction is observed in both superficial (SS) and deep stroma (DS). In these phases versican is also immuno-
detected in the internal layer of the myometrium (M); L: Lumen; SS: Superficial Stroma; DS: Deep Stroma; M: Myometrium. 
Scale bar: 200 μm. Higher Magnification micrographs show the localization of VER inside and outside the cells in proestrus (E), 
estrus (F) and diestrus (H), and mostly outside the cells in metaestrus (G). The reaction is absent from immune cells cytoplasm 
(arrows). Scale bar: 20 μm.Reproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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V1 showed the most uniform expression across treat-
ments. V3 was not detected in estrus. GAPDH was used as
internal control (Figure 4D).
Discussion
Whereas E2 levels are high throughout the estrous cycle,
and highest in estrus, P4 levels are very low in estrus and
peak in diestrus [6]. Several reports have correlated these
fluctuations with alterations in the expression of compo-
nents of the uterine ECM, including glycosaminoglycans,
proteoglycans and growth factors [32-34]. The present
data show that the distribution and expression of VER in
the mouse uterus are highly sensitive to estrous cycle
stage, with intricate modulation of deposition in different
Immunoperoxidase for versican Figure 2 (see previous page)
Immunoperoxidase for versican. (A) E2 treatment: strong immunoreaction is present in the whole endometrial stroma, 
except in areas of edema. The reaction can be observed as a network of delicate filaments. The immunolabeling is also 
observed at the interface between the deep stroma (DS) and the myometrium (M), as well as in the myometrial internal layer; 
(B) MPA treatment: versican distribution is seen as a dense brownish network in the extracellular spaces, exclusively in the 
superficial stroma (SS); (C) E2+MPA treatment: the immunoreaction is observed as a network of thin filaments in the whole 
endometrial stroma, except at the interface between the deep stroma (DS) and the myometrium (M). (D) ovariectomized 
group: immunoreaction is absent from the uterine tissues; (E) oil control group: immunoreaction is seen underneath the lumi-
nal epithelium of the antimesometrial stroma. The negative control shows no immunoreaction (F). L: Lumen; SS: Superficial 
Stroma; DS: Deep Stroma; M: Myometrium. Scale bar: 200 μm. Higher Magnification micrographs show the localization of VER 
inside and outside the cells in the MPA (H) and oil (J) groups, and mostly outside the cells in the E2 (G) and E2+MPA (I) groups. 
The reaction is absent from immune cells cytoplasm (arrows). Scale bar: 20 μm.
Relative mRNA expression of versican in the mouse uterus Figure 3
Relative mRNA expression of versican in the mouse 
uterus. The mRNA expression was analyzed by real-time 
PCR using primers common to all splice variants, and relative 
gene expression determined by designating estrus to 1. (A) 
versican mRNA in estrus and diestrus; (B) versican mRNA 
after ovariectomy and hormone replacement. Values repre-
sent the mean + SE of determinations on three independent 
tissue preparations. # p < 0.05 vs. estrus by Student t-test; *p 
< 0.05 vs. ovx and E2; ** p < 0.001 vs. all by ANOVA.
Estrus
Ovx
Oil
E2
MPA
E2+MPA
0
1
2
3
4
***
*
R
e
l
a
t
i
v
e
m
R
N
A
l
e
v
e
l
s
(
f
o
l
d
)














0.00
0.25
0.50
0.75
1.00
1.25
#
Estrus Diestrus
R
e
l
a
t
i
v
e
m
R
N
A
l
e
v
e
l
s
(
f
o
l
d
)
Expression of versican isoforms Figure 4
Expression of versican isoforms. Gel analysis of products 
generated by RT-PCR using specific primer sets for versican 
V0, V1, V2 and V3. Note the presence of V0 (left panel), V1 
(right panel) (A) and V3 (C), but the absence of V2 (B). 
GAPDH internal control shows uniform expression in all 
groups studied (D). Total RNA isolated from whole mouse 
uterus from all groups studied (n = 5). 1- Diestrus; 2- Estrus; 
3- E2; 4- MPA; 5- E2+MPA; 6- ovx; 7- oil; 8- UMRR (Univer-
sal Mouse Reference RNA); 9- ovary; * – negative control.Reproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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tissue layers. Furthermore, hormone replacement studies
have revealed that exogenous estrogen and combined
estrogen/progestin have profound influences on the ECM
that differ in different tissue layers.
Immunolocalization shows VER in endometrial ECM in
both proestrus and estrus, with undetectable levels in
myometrium in proestrus and clearly increasing levels in
myometrium in estrus. This may indicate a basal level of
transcription in unstimulated endometrial stromal cells,
in keeping with the presence of mRNA in uterine tissue
from ovariectomized animals. Ovariectomy leads to loss
of VER deposition in both endometrium and myo-
metrium. The oil control group shows a discrete immuno-
reaction restricted to a narrow area of the superficial
stroma mainly in the antimesometrial stroma. This dis-
crete protein deposition may be related to basal levels of
estrogen produced by the adrenal glands that remain after
ovariectomy. In addition, there is a constitutive expres-
sion of ER and PR even after ovariectomy [35]. Increasing
estrogen appears to stimulate the deposition of VER in the
ECM of the inner myometrial layer at estrus. In keeping
with this idea, after estrogen replacement, VER is also seen
in the endometrial stroma and inner layer of the myo-
metrium. Thus estrogen has a powerful effect on VER in
uterine ECM. Surprisingly, however, VER mRNA is main-
tained at equal levels in ovariectomized control uterus
and after estrogen stimulation. It is possible that changes
in VER mRNA in different layers may be obscured in the
whole-tissue mRNA analysis. However, it is equally possi-
ble that estrogenic control of VER is not exerted through
mRNA abundance. Versican expression may be regulated
by specific proteases, as previously demonstrated in other
models [36]. ADAMTS-1 and 4 are versicanases, and are
regulated by sexual hormones [37]. Moreover, ADAMTS-
1, 4 and 5 are modulated in the mouse ovary and
ADAMTS-1 is present in the mouse uterus [38,39]. Also
ECM changes occur on a longer timescale than those gen-
erally seen in intracellular compartments.
In diestrus there is a striking change in the myometrium
which is now VER-negative, while the protein remains
detectable in endometrium. At mRNA level there is a
marked drop in abundance, suggesting that before die-
strus, myometrial mRNA was quantitatively dominant.
These data suggest that P4 in combination with estradiol
acts to inhibit VER transcription in myometrium, adding
supporting evidence that hormone responses in this tissue
compartment are distinct from those in endometrium.
After the hormone replacement regime in which estradiol
was followed either by MPA, or MPA in combination with
estradiol, quite different effects were seen. MPA alone pro-
duced strong VER expression in the superficial endome-
trial stroma, no staining in the deep stroma or
myometrium, and yet a doubling of total mRNA relative
to the level seen in control animals. Since estrogen alone
produces relatively uniform VER deposition in both
endometrium and myometrium, this series of experi-
ments may suggest that MPA stimulates loss of VER from
ECM, and that this may be followed by de novo synthesis
in the superficial stroma, with high levels of VER mRNA
in this layer alone. In this situation it appears that
endometrial mRNA must be quantitatively dominant.
Additionally, in diestrus, proestrus and MPA groups, the
immunoreaction is observed in the ECM, as well as inside
the cells, whereas in metaestrus, E2 and E2+MPA groups
most of the reaction is seen outside the cells of the
endometrial stroma, suggesting a kinetics of synthesis and
secretion orchestrated by ovarian hormones.
The presence of V0, V1 and V3 mRNA variants was also
shown in the mouse uterus. mRNA encoding the V3 iso-
form becomes undetectable in the estrus phase, support-
ing a general conclusion that VER mRNA is altering
dynamically during the cycle, and providing evidence for
hormonal regulation of mRNA splicing. Other workers
have detected VER isoforms in reproductive tract tissues:
Dours-Zimmermann and Zimmermann [40] showed V0
and V1 in human myometrium. VER expression is very
low in the cervix of non-pregnant women, but increases
considerably in pre-term pregnancy and at labor [27].
Recently, Ruscheinsky et al. [28] studied the expression of
HA and VER in the mouse cervix and evidenced V1 as the
most abundant isoform. There is no clear evidence that V0
and V1 play distinct roles and they are generally co-
expressed [41]. Isoforms with the exception of V2 were
found in the mouse and bovine ovary [29,42]. The V3 iso-
form lacks the CS attachment sites and its role in the ECM
is likely to be distinct from V0 and V1. However, available
antibodies do not recognize V3, so the staining reported
here must be regarded as representing only V0 and V1.
Further work is required to define the distribution of the
V3 protein isoform and its functional role.
Uterine stroma is compartmentalized into superficial and
deep zones with distinct cell populations [17,43]. Indeed,
morphological differences observed between rounded
cells in the superficial stroma and spindle-shaped cells in
the deep stroma may be related to the formation of a VER-
rich pericellular matrix in the former environment. ECM
may influence the tension exerted on cells, in turn affect-
ing cell shape and behavior [20,44]. In vitro experiments
have revealed that HA- and VER-rich pericellular matrix is
related to cell detachment and mitotic cell rounding [45].
Versican accumulation in the superficial stroma in die-
strus and after MPA treatment matches high levels of pro-
liferating cells (data not shown).
Furthermore, the transdifferentiation of endometrial
fibroblasts into decidual cells requires the expression ofReproductive Biology and Endocrinology 2009, 7:60 http://www.rbej.com/content/7/1/60
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connexins and gap junction formation [46]. Recent stud-
ies showed that VER is able to enhance the expression of
connexin 43 in vitro [47]. As versican is expressed at the
maternal-fetal interface, we may speculate a role for this
proteoglycan in embryo implantation.
Importantly, MPA activates both the progesterone and
androgen receptors. Androgen receptor is expressed in
mouse uterine stroma [48] and has been shown to play a
role in decidualization in synergy with the PR [49]. Since
androgens are likely to be active during the estrous cycle
along with progesterone, MPA is an appropriate choice of
ligand for hormone replacement studies. In addition, a
previous study demonstrated that proper decidualization
occurs when using MPA to stimulate decidual differentia-
tion [50]. However, its effects are not interpretable solely
in terms of actions at the PR.
Another variable in the system that requires further atten-
tion is VER mRNA half-life, as steroid hormones are able
to regulate gene expression by altering the stability of
mRNAs and the ratio of activity of RNAses and their inhib-
itors [51-53]. Furthermore, hormone regulation of splic-
ing, the kinetics of translation and post-translational
modification, kinetics of ECM deposition and localiza-
tion, and the regulation and activation of proteases and
glycosidases that degrade VER must all be considered.
However, we anticipate that the dramatic hormonal
effects unveiled in the present study will stimulate further
investigations of these regulatory events in the ECM and
their role in preparing the uterus to accept and support a
developing embryo.
Conclusion
In conclusion, the distribution and expression of VER in
the mouse uterus are highly sensitive to estrous cycle stage
and modulated by estrogen and progesterone, each hor-
mone acting in a tissue specific manner. Furthermore,
hormonal control of VER appears not to be exerted only
through mRNA abundance. Other factors such as specific
proteases, as well as mRNA stability, may be modulated
by ovarian hormones.
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